B. Riley Securities Maintains Buy on Lineage Cell Therapeutics, Lowers Price Target to $3
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst Mayank Mamtani maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and lowers the price target from $4 to $3.
B. Riley Securities analyst Mayank Mamtani maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and lowers the price target from $4 to $3.